Key Performance
More- Earnings Score: N/A
- Momentum Score: 73
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A proposed class action settlement of $9,750,000 has been approved by the United States District Court for the District of Connecticut on behalf of purchasers of BioXcel Therapeutics securities between March 9, 2023 and June 28, 2023. A hearing is scheduled for September 2, 2026 to determine if the settlement is fair and reasonable. Class members must submit proof of claim by June 30, 2026 to share in the settlement fund.
03/23/2026, 8:00 AM • GlobeNewswire
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
BioXcel Therapeutics announced a registered direct offering of 4.5 million shares of common stock and accompanying warrants at $1.739 per share, raising approximately $8.0 million in gross proceeds. The company also agreed to reduce exercise prices on previously issued warrants held by the investor. The offering is expected to close on March 11, 2026.
03/10/2026, 2:36 PM • GlobeNewswire
BioXcel Therapeutics will ring the Nasdaq Closing Bell to celebrate its breakthrough progress in treating agitation associated with bipolar disorders and schizophrenia, highlighting the successful completion of its SERENITY At-Home pivotal trial.
10/13/2025, 7:00 AM • GlobeNewswire
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
BioXcel Therapeutics announced it has regained compliance with Nasdaq's market value listing requirements after previously being notified of non-compliance in March 2025.
09/18/2025, 7:00 AM • GlobeNewswire
BioXcel Therapeutics reported positive results from its SERENITY At-Home Phase 3 trial for BXCL501, demonstrating safety and potential for at-home treatment of agitation in bipolar and schizophrenia patients. The company plans to submit a supplemental New Drug Application (sNDA) in Q1 2026.
08/27/2025, 8:00 AM • GlobeNewswire
BioXcel Therapeutics will host an investor call on August 27, 2025, to review topline data from its SERENITY At-Home Phase 3 trial evaluating BXCL501's safety for treating agitation in bipolar disorders and schizophrenia patients.
08/26/2025, 4:00 PM • GlobeNewswire
BioXcel Therapeutics received positive FDA feedback for its supplemental New Drug Application (sNDA) to expand IGALMI's label for at-home treatment of agitation in bipolar disorders and schizophrenia, with sNDA submission expected in Q1 2026.
08/18/2025, 7:00 AM • GlobeNewswire
3 Supercharged Stocks Flashing Strong Momentum Signals
Three stocks - BioXcel Therapeutics, Telos, and Jumia - have shown significant momentum gains, with substantial price increases and strong performance in Benzinga's momentum rankings over the past week.
08/13/2025, 12:33 PM • Benzinga
The neuroendocrine prostate cancer treatment market is expected to grow significantly between 2025-2034, driven by novel therapies and diagnostic advancements, despite challenges in treatment for older patients.
08/04/2025, 1:00 PM • GlobeNewswire
BioXcel Therapeutics completed its SERENITY At-Home Phase 3 clinical trial for BXCL501, an investigational treatment for agitation in bipolar disorders and schizophrenia. The study enrolled over 200 patients across 22 sites, with topline data expected this month to support a potential supplemental New Drug Application.
08/01/2025, 7:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.